PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company's commitment to advancing treatments for neurological disorders.
纽约塔里敦，2024年5月7日（GLOBE NEWSWIRE）——通过IBN——专注于推进神经系统疾病治疗的生物制药公司PaxMedica, Inc.（场外交易代码：PXMD）根据其从纳斯达克股票市场过渡的情况提供了公司最新情况，强调这一变化不会影响该公司推进神经系统疾病治疗的承诺。
Howard Weisman, CEO of PaxMedica, affirmed, "Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further explore the potential for anti-purinergic therapies to address the core symptoms of autism spectrum disorder (ASD)."
PaxMedica 首席执行官霍华德·韦斯曼申明：“我们在 PAX-101 保密协议提交方面取得进展的决心没有受到影响，我们对进一步探索抗嘌呤能疗法解决自闭症谱系障碍 (ASD) 核心症状潜力的临床项目承诺也没有受到影响。”
The company is preparing to file a New Drug Application (NDA) with the FDA for the use of suramin in treating Human African Trypanosomiasis (HAT) as it has previously reported. Suramin has been recognized for nearly a century as a standard treatment for HAT in East Africa.
正如其先前报道的那样，该公司正准备向美国食品药品管理局提交新药申请（NDA），以使用舒拉明治疗非洲人类锥虫病（HAT）。近一个世纪以来，舒拉明一直被公认为东非HAT的标准治疗方法。
In April 2024, PaxMedica responded to an urgent request from Malawi for an emergency release of suramin, underscoring the company's commitment to addressing global health crises.
2024年4月，PaxMedica回应了马拉维提出的紧急释放舒拉明的紧急请求，这突显了该公司对解决全球健康危机的承诺。
"We are not just continuing; we are intensifying our efforts to achieve significant milestones for these programs by the end of this year," Weisman added. "We are on track to submit an NDA for PAX-101, and potentially secure an FDA Priority Review Voucher if approved."
韦斯曼补充说：“我们不仅在继续；我们还在加紧努力，争取在今年年底之前实现这些计划的重大里程碑。”“我们有望提交 PAX-101 的保密协议，如果获得批准，我们有可能获得美国食品药品管理局的优先审查凭证。”
This proactive approach illustrates PaxMedica's dedication to advancing healthcare solutions globally.
这种积极的方法表明了PaxMedica致力于在全球范围内推进医疗保健解决方案的决心。